<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Immunol</journal-id><journal-id journal-id-type="iso-abbrev">Front Immunol</journal-id><journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id><journal-title-group><journal-title>Frontiers in Immunology</journal-title></journal-title-group><issn pub-type="epub">1664-3224</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.3389/fimmu.2019.01097</article-id><article-categories><subj-group subj-group-type="heading"><subject>Immunology</subject><subj-group><subject>Original Research</subject></subj-group></subj-group></article-categories><title-group><article-title>Identification and <italic>in vivo</italic> Efficacy Assessment of Approved Orally Bioavailable Human Host Protein-Targeting Drugs With Broad Anti-influenza A Activity</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Enkirch</surname><given-names>Theresa</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/655323/overview"/></contrib><contrib contrib-type="author"><name><surname>Sauber</surname><given-names>Svenja</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Anderson</surname><given-names>Danielle E.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/607728/overview"/></contrib><contrib contrib-type="author"><name><surname>Gan</surname><given-names>Esther S.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kenanov</surname><given-names>Dimitar</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Maurer-Stroh</surname><given-names>Sebastian</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/627392/overview"/></contrib><contrib contrib-type="author"><name><surname>von Messling</surname><given-names>Veronika</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="corresp" rid="c001"><sup>*</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/599137/overview"/></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Programme in Emerging Infectious Diseases, Duke-NUS Medical School</institution>, <addr-line>Singapore</addr-line>, <country>Singapore</country></aff><aff id="aff2"><sup>2</sup><institution>Veterinary Medicine Division, Paul-Ehrlich-Institut</institution>, <addr-line>Langen</addr-line>, <country>Germany</country></aff><aff id="aff3"><sup>3</sup><institution>Biomolecular Function Discovery Division, Bioinformatics Institute, Agency for Science, Technology and Research</institution>, <addr-line>Singapore</addr-line>, <country>Singapore</country></aff><aff id="aff4"><sup>4</sup><institution>Department of Biological Sciences, National University of Singapore</institution>, <addr-line>Singapore</addr-line>, <country>Singapore</country></aff><author-notes><fn fn-type="edited-by"><p>Edited by: Abhijeet Anil Bakre, University of Georgia, United States</p></fn><fn fn-type="edited-by"><p>Reviewed by: Rong Hai, University of California, Riverside, United States; Michael Schotsaert, Icahn School of Medicine at Mount Sinai, United States</p></fn><corresp id="c001">*Correspondence: Veronika von Messling <email>veronika.vonmessling@bmbf.bund.de</email></corresp><fn fn-type="other" id="fn001"><p>This article was submitted to Vaccines and Molecular Therapeutics, a section of the journal Frontiers in Immunology</p></fn></author-notes><pub-date pub-type="epub"><day>05</day><month>6</month><year>2019</year></pub-date><pub-date pub-type="collection"><year>2019</year></pub-date><volume>10</volume><elocation-id>1097</elocation-id><history><date date-type="received"><day>31</day><month>10</month><year>2018</year></date><date date-type="accepted"><day>30</day><month>4</month><year>2019</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2019 Enkirch, Sauber, Anderson, Gan, Kenanov, Maurer-Stroh and von Messling.</copyright-statement><copyright-year>2019</copyright-year><copyright-holder>Enkirch, Sauber, Anderson, Gan, Kenanov, Maurer-Stroh and von Messling</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><p>The high genetic variability of influenza A viruses poses a continual challenge to seasonal and pandemic vaccine development, leaving antiviral drugs as the first line of defense against antigenically different strains or new subtypes. As resistance against drugs targeting viral proteins emerges rapidly, we assessed the antiviral activity of already approved drugs that target cellular proteins involved in the viral life cycle and were orally bioavailable. Out of 15 candidate compounds, four were able to inhibit infection by 10- to 100-fold without causing toxicity, <italic>in vitro</italic>. Two of the drugs, dextromethorphan and ketotifen, displayed a 50% effective dose between 5 and 50 &#x003bc;M, not only for the classic H1N1 PR8 strain, but also for a pandemic H1N1 and a seasonal H3N2 strain. Efficacy assessment in mice revealed that dextromethorphan consistently resulted in a significant reduction of viral lung titers and also enhanced the efficacy of oseltamivir. Dextromethorphan treatment of ferrets infected with a pandemic H1N1 strain led to a reduction in clinical disease severity, but no effect on viral titer was observed. In addition to identifying dextromethorphan as a potential influenza treatment option, our study illustrates the feasibility of a bioinformatics-driven rational approach for repurposing approved drugs against infectious diseases.</p></abstract><kwd-group><kwd>influenza A virus</kwd><kwd>drug repurposing</kwd><kwd>antiviral (H1N1 and H3N2) activity</kwd><kwd>animal models</kwd><kwd>host protein-targeting drugs</kwd></kwd-group><funding-group><award-group><funding-source id="cn001">Deutsches Zentrum f&#x000fc;r Infektionsforschung<named-content content-type="fundref-id">10.13039/100009139</named-content></funding-source></award-group><award-group><funding-source id="cn002">Bundesministerium f&#x000fc;r Gesundheit<named-content content-type="fundref-id">10.13039/501100003107</named-content></funding-source></award-group><award-group><funding-source id="cn003">Ministry of Health -Singapore<named-content content-type="fundref-id">10.13039/501100001350</named-content></funding-source></award-group><award-group><funding-source id="cn004">Agency for Science, Technology and Research<named-content content-type="fundref-id">10.13039/501100001348</named-content></funding-source></award-group></funding-group><counts><fig-count count="4"/><table-count count="2"/><equation-count count="0"/><ref-count count="61"/><page-count count="10"/><word-count count="7074"/></counts></article-meta></front><body><sec sec-type="intro" id="s1"><title>Introduction</title><p>Influenza A viruses are one of the most important respiratory pathogens. Annual epidemics represent an important disease burden and cause an estimated 250,000&#x02013;500,000 deaths worldwide, and occasional pandemics are associated with increased morbidity and mortality (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B2" ref-type="bibr">2</xref>). Influenza A viruses belong to the <italic>Orthomyxoviridae</italic> family and have a segmented negative-sense RNA genome (<xref rid="B3" ref-type="bibr">3</xref>). Their envelope contains the ion channel forming M2 protein and the hemagglutinin (HA), and neuraminidase (NA) glycoproteins. Based on the antigenic properties of these viral glycoproteins, influenza A viruses are classified into different subtypes. To date, 18 hemagglutinin (H1&#x02013;H18) and 11 neuraminidase (N1&#x02013;N11) subtypes have been identified (<xref rid="B3" ref-type="bibr">3</xref>, <xref rid="B4" ref-type="bibr">4</xref>).</p><p>With the exception of bat-associated subtypes (<xref rid="B4" ref-type="bibr">4</xref>), all influenza A virus subtypes can be found in wild aquatic birds, which are their natural reservoir. From these animals the virus can spread to domestic poultry or directly to humans and other mammalian hosts (<xref rid="B5" ref-type="bibr">5</xref>). Pandemics occur if such a new subtype acquires the ability to infect and transmit in the human population. Over the last 20 years, there have been regular introductions of H5N1 strains and occasional cases of H7N1 and H9N2 infections, mostly associated with outbreaks in poultry (<xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B7" ref-type="bibr">7</xref>). Since March 2013, human infections with a previously undescribed H7N9 virus were observed, which also circulates in domestic birds without causing severe disease (<xref rid="B8" ref-type="bibr">8</xref>). Even though the production of influenza vaccines is well established, and the regulatory process allows for rapid strain update or exchange, it takes 4&#x02013;6 months until a vaccine against a newly emerging subtype is available in sufficient quantities (<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B9" ref-type="bibr">9</xref>).</p><p>Thus, antiviral drugs are an essential component of pandemic response scenarios and play an important role in reducing disease severity during seasonal influenza epidemics. Two classes of approved drugs against influenza A virus infections have been available for years: adamantane-based M2 ion channel blockers, which prevent acidification of the endosome and therefore release of the viral particles into the cytosol (<xref rid="B10" ref-type="bibr">10</xref>), and neuraminidase inhibitors, which prevent the release of newly formed viral particles from infected cells (<xref rid="B11" ref-type="bibr">11</xref>). In both cases, resistant viruses emerged rapidly after the onset of widespread use, and at this time, all circulating human influenza A viruses are adamantane-resistant (<xref rid="B12" ref-type="bibr">12</xref>), and the number of neuraminidase inhibitor-resistant viruses is rapidly increasing (<xref rid="B13" ref-type="bibr">13</xref>). Earlier this year, baloxavir marboxil, a cap-dependent endonuclease inhibitor, has been licensed in Japan for the treatment of influenza virus infections (<xref rid="B14" ref-type="bibr">14</xref>), and favipiravir, an inhibitor of the RNA-dependent RNA polymerase, is in advanced clinical development stages (<xref rid="B15" ref-type="bibr">15</xref>), so additional treatment options are becoming available. Repurposed drugs targeting cellular instead of viral proteins are considered a promising complement, on the one hand because of the potential for efficacy against a broader range of viruses using the respective pathway, and on the other hand due to the reduced probability for acquisition of resistance-conferring mutations without fitness cost (<xref rid="B16" ref-type="bibr">16</xref>, <xref rid="B17" ref-type="bibr">17</xref>).</p><p>Whole genome siRNA screens have yielded a list of promising candidate proteins and pathways involved in the influenza virus life cycle (<xref rid="B18" ref-type="bibr">18</xref>&#x02013;<xref rid="B21" ref-type="bibr">21</xref>). Watanabe et al. previously described a network of 128 consensus human host genes that were identified in at least 2 separate of these experimental screens to be important for the virus life cycle in the host cell (<xref rid="B22" ref-type="bibr">22</xref>). In this study, we re-analyzed the network of consensus cellular candidate proteins from these screens and overlapped it with databases of known cellular targets of already licensed drugs, which would thus be immediately available in case of a pandemic. The anti-influenza activity of the top candidates was then first evaluated <italic>in vitro</italic>, followed by an efficacy assessment of the most promising drugs in mice and ferrets.</p></sec><sec sec-type="materials and methods" id="s2"><title>Materials and Methods</title><sec><title>Cells and Viruses</title><p>Madin-Darby canine kidney (MDCK) cells (ATCC CCL-34) cells were maintained in Dulbecco's modified eagle medium (DMEM) supplemented with 5% fetal calf serum (FCS), and 1% L-glutamine at 37&#x000b0;C. The influenza A virus strains H1N1 A/Puerto Rico/8/34 (PR8, (<xref rid="B23" ref-type="bibr">23</xref>), H3N2 A/Victoria/36/2011 (H3N2, kind gift from Ralf Wagner, Paul-Ehrlich-Institut), and H1N1 pdm09A/Mexico/InDRE4487/2009 [H1N1pdm09, (<xref rid="B24" ref-type="bibr">24</xref>)] were propagated in MDCK cells cultivated in DMEM supplemented with 0.75 &#x003bc;g/ml tolylsulfonyl-phenylalanyl-chloromethyl-ketone (TPCK)-trypsin (Sigma) at 37&#x000b0;C. After 12&#x02013;24 h, the virus-containing supernatant was harvested, centrifuged at 4&#x000b0;C for 5 min at 800 <italic>g</italic> to remove cell debris, aliquoted, and stored at &#x02212;80&#x000b0;C. Virus titers were determined by limited-dilution method and expressed as 50% tissue culture infectious doses per ml (TCID<sub>50</sub>/ml).</p></sec><sec><title>Bioinformatics Analysis</title><p>Watanabe et al. previously described a network of 128 consensus human host genes that were identified in at least two separate experimental screens to be important for the virus life cycle in the host cell (<xref rid="B22" ref-type="bibr">22</xref>). The 128 gene nodes from this network were originally connected by 431 edges, which constituted the basis for our analysis. We re-analyzed the network and added new edges from co-expression and protein-protein interaction data. For the co-expression, 62 human microarray datasets from NCBI GEO (<xref rid="B25" ref-type="bibr">25</xref>) with minimum 25 samples available (to limit to larger studies) were used to search for correlations between pairs of genes. For a given gene, the Pearson correlation coefficient (PCC) is calculated for every other gene over the 62 datasets. PCC &#x0003e;0.5 or smaller than &#x02212;0.5 was considered for establishing 4,482 co-expression links between gene pairs. Five hundred and seventy-four protein-protein interaction links were derived from our in-house integrated protein interaction database, which is a collection of experimentally determined protein-protein interactions and contains data from 10 publicly available resources (<xref rid="B26" ref-type="bibr">26</xref>). 319 virus and gene/protein interactions were retained from the network of 128 consensus human host genes (<xref rid="B22" ref-type="bibr">22</xref>). A Perl script was written to format the nodes and edges for GraphViz Version 2.38 [<ext-link ext-link-type="uri" xlink:href="http://www.graphviz.org">http://www.graphviz.org</ext-link>] and the network drawn with layout from the NEATO spring-based algorithm [<ext-link ext-link-type="uri" xlink:href="http://www.graphviz.org/pdf/neatoguide.pdf">http://www.graphviz.org/pdf/neatoguide.pdf</ext-link>]. 14 gene targets of FDA-approved drugs were identified among the 128 nodes by a custom Perl script that identifies direct as well as alternative gene name matches in the DrugBank flat file version 3.0 (<xref rid="B27" ref-type="bibr">27</xref>). Fifteen drugs were selected based on oral bioavailability as well as different degrees of connectivity of the respective target genes in our network, price, and low organism toxicity.</p></sec><sec><title><italic>In vitro</italic> Influenza Virus Inhibition Assays</title><p>All compounds were purchased from Sigma and diluted in either water, phosphate buffer saline (PBS), or dimethyl sulfoxide (DMSO, Sigma) to stock concentrations of 0.5 M, and DMEM was used for all further dilutions. For the initial efficacy screen, 12-well plates seeded with MDCK cells were pretreated with the respective compound for 8 h with 50 or 500 &#x003bc;M of each compound. The cells were then washed with PBS, infected with the PR8 at an MOI of 0.01, and cultivated in TPCK-DMEM (0.75 &#x003bc;g/ml) containing the same drug concentration. Sixteen hour post-infection, the supernatant was stored at &#x02212;80&#x000b0;C, and the amount of virus was quantified by limited dilution method and expressed as 50% tissue culture infectious dose (TCID<sub>50</sub>). To evaluate the inhibitory effect of the lead compounds in more detail, the experiment was repeated including additional drug concentrations and different influenza A strains.</p><p>For the calculation of the 50% effective concentration (EC<sub>50</sub>), a modified plaque reduction assay was used (<xref rid="B28" ref-type="bibr">28</xref>). Briefly, MDCK cells were seeded in 6-well plates and pretreated for 8 h with the drug of interest at 5-fold decreasing doses. The cells were then infected with the respective virus at a dose that yields 15&#x02013;45 plaques per well in the absence of treatment. After incubation for 1 h at 37&#x000b0;C, the cells were washed with PBS, and overlayed with avicel (Sigma) containing the respective drug concentration. After 3 days, the overlay was removed and the wells were stained with 1% crystal violet solution (Sigma), and plaques were counted. GraphPad 6 was used for curve fitting and EC<sub>50</sub> calculation.</p></sec><sec><title>MTT Assay</title><p>The MTT assay was performed according to the manufacturer's protocol (Thermo Fisher Vybrant MTT Cell Proliferation Assay Kit). Briefly, MDCK cells grown in a 96-well-plate were treated with the respective drugs at 5-fold descending concentrations starting at 500 mM or left untreated. After 24 h, medium was replaced by PBS containing 1 mM MTT. After incubation for 4 h at 37&#x000b0;C, supernatants were removed, mixed with DMSO and further incubated for 10 min at 37&#x000b0;C before absorption was measured at 562 nm using a PHOmo Microplate reader. To calculate the relative cytotoxicity, the absorbance of untreated cells was set to 1. The 50% cytotoxic concentration (CC<sub>50</sub>) was calculated using GraphPad 6, and the selectivity index (SI) represents the ratio of CC<sub>50</sub> to EC<sub>50</sub>.</p></sec><sec><title><italic>In vivo</italic> Efficacy Assessments</title><p>All animal experiments were reviewed and approved by the SingHealth IACUC Committee or the German competent authority (Regierungspraesidium Darmstadt) and carried out according to Singaporean or German Animal Welfare Law, respectively. Groups of 4&#x02013;6 week-old female C57BL/6 mice (Janvier Labs) were anesthetized by intraperitoneal injection of ketamine/xylazine (100/5 mg/kg), followed by intranasal infection with 1 &#x000d7; 10<sup>3</sup> TCID<sub>50</sub> of PR8 in 30 &#x003bc;l of DMEM. Based on the tolerated doses published for the respective drug (<xref rid="B29" ref-type="bibr">29</xref>), a dose-finding study was performed, resulting in the following doses used in all mouse experiments: 50 mg/kg/day for oseltamivir phosphate, 40 mg/kg/day for naltrexone, 100 mg/kg/day gallium nitrate, 80 mg/kg/day for ketotifen, and 60 mg/kg/day for dextromethorphan. Animals were gavaged once daily starting 1 day before infection. Three days after infection, the mice were sacrificed and the viral titer in the lungs was determined. Toward this, the lung was weighed and homogenized in 500 &#x003bc;l DMEM with 3 &#x000d7; concentrated penicillin/streptomycin using 2 ml homogenizer tubes (Lysing matrix D, MP Biomedicals) and the Precellys 24-Dual Homogenizer (Peqlab). The titer in the supernatants was quantified by limited dilution method on MDCK cells and expressed as TCID<sub>50</sub>/g.</p><p>To evaluate the treatment effect on disease severity in a more clinically relevant situation, groups of male, and female adult European ferrets (<italic>mustela putorius furo</italic>, bred in-house) without antibodies against circulating seasonal influenza A virus strains were treated orally every 8 h with either oseltamivir (2.5 mg/kg, Roche) or dextromethorphan (2 mg/kg, Procter, &#x00026; Gamble) following the manufacturer's dosing and treatment recommendation, starting 24 h before infection, or left untreated. For infection, animals were anesthetized with ketamine and medetomidine (2/0.2 mg/kg), and then inoculated intranasally with 1 &#x000d7; 10<sup>5</sup> TCID<sub>50</sub> H1N1pdm09. Treatment was continued until day 4 post-infection. During that time, clinical signs, body temperature, and weight were assessed twice daily, and then daily until day 7. Respiratory signs, sneezing, nose exudates, congestion, and activity were scored using a 0&#x02013;1&#x02013;2 scale. Zero indicates minimal deviations of the physiologic state, 1 indicates moderate nasal discharge, congestion, and/or occasional sneezing, and calm demeanor, and 2 indicates severe nasal discharge and/or labored breathing, dyspnea, frequent sneezing, and depression. Nasal washes were collected every day for the first 4 days and on day 7. Toward this, 500 &#x003bc;l of PBS was administered in one nostril and expectorate was collected in 50 ml centrifuge tubes. This procedure was repeated twice to obtain a minimal volume of 400 &#x003bc;l. The virus titer of the nasal washes was determined by limited dilution method.</p></sec><sec><title>Statistical Analyses</title><p>Statistically significant differences between animal groups were determined using one-way analysis of variance (ANOVA) with Dunnett's Multiple Comparison Test for mice treatment group comparison and Tukey's Multiple Comparison Test for ferret clinical score comparison using GraphPad 6.</p></sec></sec><sec sec-type="results" id="s3"><title>Results</title><sec><title>Identification of Approved Drugs Targeting Cellular Proteins Involved in the Influenza Virus Life Cycle</title><p>Whole genome siRNA screens using different influenza A virus strains and cell lines have yielded a list of cellular proteins that are required in the influenza virus life cycle (<xref rid="B22" ref-type="bibr">22</xref>). While it is in most cases unknown if these identified proteins are directly interacting with viral proteins, or if they act indirectly, drugs that modulate their expression levels or activity may also inhibit influenza virus. Therefore, we computationally searched for FDA-approved drugs annotated in DrugBank (<xref rid="B27" ref-type="bibr">27</xref>) to target any of the genes in our updated host factor network generated by a meta-analysis of available influenza virus siRNA screen data sets (<xref ref-type="fig" rid="F1">Figure 1</xref>). This bioinformatics analysis yielded 23 candidates, of which 15 drugs linked to 14 different host genes were chosen for further characterization based on oral bioavailability, since this would be a prerequisite for widespread use during a severe epidemic or pandemic. In addition, price, low organism toxicity, commercial availability, and level of connectivity of the respective target genes in our network were also taken into consideration (<xref rid="T1" ref-type="table">Table 1</xref>).</p><fig id="F1" position="float"><label>Figure 1</label><caption><p>Identification of candidate drugs. Network of influenza host factors with drug targets highlighted. From the network of 128 consensus human host genes (<xref rid="B22" ref-type="bibr">22</xref>), 319 virus and gene/protein interactions were retained. Among the 128 nodes, 14 gene targets of FDA-approved drugs were identified by a custom Perl script that identifies direct as well as alternative gene name matches in the DrugBank flat file version 3.0 (<xref rid="B27" ref-type="bibr">27</xref>).</p></caption><graphic xlink:href="fimmu-10-01097-g0001"/></fig><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Inhibition of influenza A virus replication by licensed drugs with Drug ID and cellular targets identified by bioinformatics analysis.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"><bold>Drug Candidate</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>Drugbank ID</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Annotated Target</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Inhibitory effect</bold></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Arsenic trioxide</td><td valign="top" align="center" rowspan="1" colspan="1">DB01169</td><td valign="top" align="left" rowspan="1" colspan="1">AKT1, JUN, MAPK1</td><td valign="top" align="left" rowspan="1" colspan="1">Excluded; high organism toxicity</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Tiludronate</td><td valign="top" align="center" rowspan="1" colspan="1">DB01133</td><td valign="top" align="left" rowspan="1" colspan="1">ATP6V1A</td><td valign="top" align="left" rowspan="1" colspan="1">Excluded; no oral administration</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Palifermin</td><td valign="top" align="center" rowspan="1" colspan="1">DB00039</td><td valign="top" align="left" rowspan="1" colspan="1">FGFR2</td><td valign="top" align="left" rowspan="1" colspan="1">Excluded; no oral administration</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Interferon gamma-1b</td><td valign="top" align="center" rowspan="1" colspan="1">DB00033</td><td valign="top" align="left" rowspan="1" colspan="1">IFNGR2</td><td valign="top" align="left" rowspan="1" colspan="1">Excluded; no oral administration; costly</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Pentazocine</td><td valign="top" align="center" rowspan="1" colspan="1">DB00652</td><td valign="top" align="left" rowspan="1" colspan="1">OPRS1</td><td valign="top" align="left" rowspan="1" colspan="1">Excluded; controlled substance</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Remoxipride</td><td valign="top" align="center" rowspan="1" colspan="1">DB00409</td><td valign="top" align="left" rowspan="1" colspan="1">OPRS1</td><td valign="top" align="left" rowspan="1" colspan="1">Excluded; no longer licensed</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Gadopentetate dimeglumine</td><td valign="top" align="center" rowspan="1" colspan="1">DB00789</td><td valign="top" align="left" rowspan="1" colspan="1">PGD</td><td valign="top" align="left" rowspan="1" colspan="1">Excluded; no oral administration</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Urokinase</td><td valign="top" align="center" rowspan="1" colspan="1">DB00013</td><td valign="top" align="left" rowspan="1" colspan="1">PLAU</td><td valign="top" align="left" rowspan="1" colspan="1">Excluded; no oral administration</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Isoproterenol</td><td valign="top" align="center" rowspan="1" colspan="1">DB01064</td><td valign="top" align="left" rowspan="1" colspan="1">MAPK1</td><td valign="top" align="left" rowspan="1" colspan="1">toxic</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Alendronate</td><td valign="top" align="center" rowspan="1" colspan="1">DB00630</td><td valign="top" align="left" rowspan="1" colspan="1">ATP6V1A</td><td valign="top" align="left" rowspan="1" colspan="1">toxic</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Vinblastine</td><td valign="top" align="center" rowspan="1" colspan="1">DB00570</td><td valign="top" align="left" rowspan="1" colspan="1">JUN</td><td valign="top" align="left" rowspan="1" colspan="1">toxic</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Irbesartan</td><td valign="top" align="center" rowspan="1" colspan="1">DB01029</td><td valign="top" align="left" rowspan="1" colspan="1">JUN</td><td valign="top" align="left" rowspan="1" colspan="1">toxic</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Adenosine triphosphate</td><td valign="top" align="center" rowspan="1" colspan="1">DB00171</td><td valign="top" align="left" rowspan="1" colspan="1">AKT1,TNK2</td><td valign="top" align="left" rowspan="1" colspan="1">No inhibition</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Etidronic Acid</td><td valign="top" align="center" rowspan="1" colspan="1">DB01077</td><td valign="top" align="left" rowspan="1" colspan="1">ATP6V1A</td><td valign="top" align="left" rowspan="1" colspan="1">No inhibition</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">N-Acetyl-D-Glucosamine</td><td valign="top" align="center" rowspan="1" colspan="1">DB00141</td><td valign="top" align="left" rowspan="1" colspan="1">NAGK, NAGPA</td><td valign="top" align="left" rowspan="1" colspan="1">No inhibition</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">L-Glutamic Acid</td><td valign="top" align="center" rowspan="1" colspan="1">DB00142</td><td valign="top" align="left" rowspan="1" colspan="1">SLC1A3</td><td valign="top" align="left" rowspan="1" colspan="1">No inhibition</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Thalidomide</td><td valign="top" align="center" rowspan="1" colspan="1">DB01041</td><td valign="top" align="left" rowspan="1" colspan="1">FGFR2</td><td valign="top" align="left" rowspan="1" colspan="1">No inhibition</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Amiloride</td><td valign="top" align="center" rowspan="1" colspan="1">DB00594</td><td valign="top" align="left" rowspan="1" colspan="1">PLAU</td><td valign="top" align="left" rowspan="1" colspan="1">No inhibition</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Dacarbazine</td><td valign="top" align="center" rowspan="1" colspan="1">DB00851</td><td valign="top" align="left" rowspan="1" colspan="1">PGD</td><td valign="top" align="left" rowspan="1" colspan="1">no inhibition</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Gallium nitrate</td><td valign="top" align="center" rowspan="1" colspan="1">DB05260</td><td valign="top" align="left" rowspan="1" colspan="1">ATP6V1B2</td><td valign="top" align="left" rowspan="1" colspan="1">&#x0003e;10-fold inhibition</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Naltrexone</td><td valign="top" align="center" rowspan="1" colspan="1">DB00704</td><td valign="top" align="left" rowspan="1" colspan="1">OPRS1</td><td valign="top" align="left" rowspan="1" colspan="1">&#x0003e;10-fold inhibition</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Dextromethorphan</td><td valign="top" align="center" rowspan="1" colspan="1">DB00514</td><td valign="top" align="left" rowspan="1" colspan="1">OPRS1</td><td valign="top" align="left" rowspan="1" colspan="1">&#x0003e;10-fold inhibition</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Ketotifen</td><td valign="top" align="center" rowspan="1" colspan="1">DB00920</td><td valign="top" align="left" rowspan="1" colspan="1">PGD</td><td valign="top" align="left" rowspan="1" colspan="1">&#x0003e;10-fold inhibition</td></tr></tbody></table></table-wrap></sec><sec><title>Four of the Identified Compounds Inhibit Influenza A Virus Replication</title><p>To identify candidates with influenza virus inhibitory activity, cells were pre-treated with the respective drug at 50 and 500 &#x003bc;M, and virus titers were quantified 16 h after infection with PR8, which corresponded to the peak titer in the untreated samples. Four of the compounds, isoproterenol, alendronate, vinblastine, and irbesartan, displayed pronounced toxicity at the 500 &#x003bc;M concentration, and no antiviral activity at a 10-fold lower concentration (<xref rid="T1" ref-type="table">Table 1</xref>). Adenosine triphosphate, etidronic acid, N-acetyl-D-glucosamine, L-glutamic acid, thalidomide, amiloride, and dacarbazine had no antiviral activity (<xref rid="T1" ref-type="table">Table 1</xref>). Thus, these 11 compounds were excluded from further evaluation. The four remaining compounds, gallium nitrate, naltrexone, dextromethorphan, and ketotifen, were able to inhibit infection at doses above 50 &#x003bc;M without causing toxicity (<xref rid="T1" ref-type="table">Table 1</xref>). Gallium nitrate is used to treat cancer-associated hypercalcemia, since it prevents osteoclastic activity, by inhibiting ATPase-dependent proton pumps (<xref rid="B30" ref-type="bibr">30</xref>, <xref rid="B31" ref-type="bibr">31</xref>). These pumps, including the vATPase (ATP6V1B2, <xref rid="T1" ref-type="table">Table 1</xref>) are also involved in acidification of the endosome, which may explain its inhibitory effect on influenza A viruses (<xref rid="B32" ref-type="bibr">32</xref>). Naltrexone, a competitive opioid receptor agonist which primarily targets &#x003bc;- and to a lesser extent the &#x003ba;-opioid receptors, and dextromethorphan, a &#x003c3;<sub>1</sub>-receptor, and &#x003bc;-opioid receptor agonist, can both act on the &#x003c3;<sub>1</sub>-receptor (OPRS1) (<xref rid="B33" ref-type="bibr">33</xref>). OPRS1 is involved in diverse intracellular processes (<xref rid="B34" ref-type="bibr">34</xref>), including the modulation of innate and adaptive immune responses (<xref rid="B35" ref-type="bibr">35</xref>), which may be the basis for its antiviral activity against influenza. Ketotifen, a histamine H1 receptor blocker (<xref rid="B36" ref-type="bibr">36</xref>), was found to block 6-phosphogluconate dehydrogenase (PGD) <italic>in vitro</italic> (<xref rid="B37" ref-type="bibr">37</xref>), which is upregulated in influenza A virus-infected cells (<xref rid="B38" ref-type="bibr">38</xref>).</p><p>To determine whether the antiviral activity of these four potential candidates extended to circulating seasonal H3N2 and pandemic H1N1 influenza strains, A/Victoria/36/2011 (H3N2), and A/Mexico/InDRE4487/2009 (H1N1pdm09) were included in the study. The neuraminidase inhibitor oseltamivir carboxylate was used as a positive control. Using the same experimental setup with 10-fold decreasing drug concentrations starting at 500 &#x003bc;M, oseltamivir carboxylate completely inhibited replication of all three strains at concentrations higher than 5 &#x003bc;M (<xref ref-type="fig" rid="F2">Figure 2</xref>). In contrast, all four drugs targeting cellular proteins were only able to reduce viral titers starting at concentrations around 5 &#x003bc;M (<xref ref-type="fig" rid="F2">Figure 2</xref>). This effect ranged from around 10-fold for gallium nitrate to 100-fold for naltrexone and ketotifen, and around 1,000-fold for dextromethorphan. While the extent of inhibition varied for each of the viruses, this tendency was consistently observed, thereby validating our initial findings.</p><fig id="F2" position="float"><label>Figure 2</label><caption><p>Validation and inhibitory concentration determination of candidate drugs. Replication inhibition of the different drugs. MDCK cells were pretreated for 8 h and infected with the influenza strains A/Puerto Rico/8/34 (PR8) <bold>(A)</bold>, A/Mexico/InDRE4487/2009 (H1N1pdm09) <bold>(B)</bold>, or A/Victoria/36/2011 (H3N2) <bold>(C)</bold> at a MOI of 0.01 in the presence of 10-fold serial drug dilutions. After 16 h, the supernatant was harvested and the amount of virus quantified by limited dilution method. Bars represent the average of three independent duplicate experiments, and error bars indicate the standard deviation.</p></caption><graphic xlink:href="fimmu-10-01097-g0002"/></fig><p>To calculate the EC<sub>50</sub> for each drug against the different viruses, a more sensitive modified plaque assay was used, which assesses the percent plaque reduction at the respective drug concentration (<xref rid="B28" ref-type="bibr">28</xref>). Using 5-fold decreasing drug concentrations, again starting at 500 &#x003bc;M, the EC<sub>50</sub> of oseltamivir carboxylate ranged between 5 and 200 nM, with PR8 being most effectively inhibited (EC<sub>50</sub> of 5 nM), while the EC<sub>50</sub> for H1N1pdm09 was around 200 nM (<xref rid="T2" ref-type="table">Table 2</xref>). Naltrexone inhibited both H1N1 viruses with an EC<sub>50</sub> between 5 and 50 &#x003bc;M but was less efficient against the H3N2 virus, whereas gallium nitrate, ketotifen, and dextromethorphan displayed EC<sub>50</sub> between 5 and 50 &#x003bc;M against all three viruses (<xref rid="T2" ref-type="table">Table 2</xref>). To determine the selectivity index (SI), the cytotoxic concentration for each of the drugs was determined in MDCK cells using an MTT assay. While the SI for oseltamivir carboxylate was between 2,000 and 100,000, the SI for the drugs targeting cellular proteins ranged between 10 and 1000 with the SI of dextromethorphan being between 50 and 100 across different viruses (<xref rid="T2" ref-type="table">Table 2</xref>).</p><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Fifty percent cytotoxic concentration (CC<sub>50</sub>) in MDCK cells, 50% effective concentration (EC<sub>50</sub>) measured by modified plaque reduction assay, and the resulting selectivity index (SI) of the different compounds against H1N1 and H3N2 influenza A viruses.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th valign="top" align="center" colspan="2" style="border-bottom: thin solid #000000;" rowspan="1"><bold>PR8</bold></th><th valign="top" align="center" colspan="2" style="border-bottom: thin solid #000000;" rowspan="1"><bold>pH1N1</bold></th><th valign="top" align="center" colspan="2" style="border-bottom: thin solid #000000;" rowspan="1"><bold>H3N2</bold></th></tr><tr><th rowspan="1" colspan="1"/><th valign="top" align="center" rowspan="1" colspan="1"><bold>CC<sub><bold>50</bold></sub> (&#x003bc;M)</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>EC<sub><bold>50</bold></sub> (&#x003bc;M)</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>SI</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>EC<sub><bold>50</bold></sub> (&#x003bc;M)</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>SI</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>EC<sub><bold>50</bold></sub> (&#x003bc;M)</bold></th><th valign="top" align="center" rowspan="1" colspan="1"><bold>SI</bold></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Oseltamivir</td><td valign="top" align="center" rowspan="1" colspan="1">470 &#x000b1; 12.3</td><td valign="top" align="center" rowspan="1" colspan="1">0.005 &#x000b1; 0.0004</td><td valign="top" align="center" rowspan="1" colspan="1">94,000</td><td valign="top" align="center" rowspan="1" colspan="1">0.2 &#x000b1; 0.05</td><td valign="top" align="center" rowspan="1" colspan="1">2350</td><td valign="top" align="center" rowspan="1" colspan="1">0.05 &#x000b1; 0.003</td><td valign="top" align="center" rowspan="1" colspan="1">9,400</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Naltrexone</td><td valign="top" align="center" rowspan="1" colspan="1">5233 &#x000b1; 227</td><td valign="top" align="center" rowspan="1" colspan="1">4.7 &#x000b1; 0.2</td><td valign="top" align="center" rowspan="1" colspan="1">1,113</td><td valign="top" align="center" rowspan="1" colspan="1">48.0 &#x000b1; 3.2</td><td valign="top" align="center" rowspan="1" colspan="1">109</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003e;500</td><td valign="top" align="center" rowspan="1" colspan="1">n.d.</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Gallium nitrate</td><td valign="top" align="center" rowspan="1" colspan="1">716 &#x000b1; 116</td><td valign="top" align="center" rowspan="1" colspan="1">54.8 &#x000b1; 2.2</td><td valign="top" align="center" rowspan="1" colspan="1">13.1</td><td valign="top" align="center" rowspan="1" colspan="1">55.3 &#x000b1; 2.9</td><td valign="top" align="center" rowspan="1" colspan="1">12.9</td><td valign="top" align="center" rowspan="1" colspan="1">5.7 &#x000b1; 0.9</td><td valign="top" align="center" rowspan="1" colspan="1">126</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Ketotifen</td><td valign="top" align="center" rowspan="1" colspan="1">291 &#x000b1; 14.8</td><td valign="top" align="center" rowspan="1" colspan="1">5.9 &#x000b1; 0.2</td><td valign="top" align="center" rowspan="1" colspan="1">49.3</td><td valign="top" align="center" rowspan="1" colspan="1">33.7 &#x000b1; 1.3</td><td valign="top" align="center" rowspan="1" colspan="1">8.6</td><td valign="top" align="center" rowspan="1" colspan="1">48.5 &#x000b1; 2.0</td><td valign="top" align="center" rowspan="1" colspan="1">6.0</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Dextromethorphan</td><td valign="top" align="center" rowspan="1" colspan="1">3546 &#x000b1; 11.1</td><td valign="top" align="center" rowspan="1" colspan="1">48.7 &#x000b1; 2.3</td><td valign="top" align="center" rowspan="1" colspan="1">72.8</td><td valign="top" align="center" rowspan="1" colspan="1">50.8 &#x000b1; 3.3</td><td valign="top" align="center" rowspan="1" colspan="1">69.8</td><td valign="top" align="center" rowspan="1" colspan="1">51.7 &#x000b1; 4.2</td><td valign="top" align="center" rowspan="1" colspan="1">68.6</td></tr></tbody></table></table-wrap></sec><sec><title>Prophylactic Treatment With Ketotifen or Dextromethorphan Reduces Lung Titers in Mice</title><p>To gain first insights in the ability of the four candidate drugs to reduce virus replication <italic>in vivo</italic>, C57BL/6 mice were treated orally once a day starting 1 day before infection with the respective drug. For all drugs, the initial doses were chosen based on published tolerated doses (<xref rid="B29" ref-type="bibr">29</xref>, <xref rid="B39" ref-type="bibr">39</xref>&#x02013;<xref rid="B41" ref-type="bibr">41</xref>), and optimal concentrations were determined in an initial dose-finding study (data not shown). Comparison of lung virus titers at peak infection and survival curves revealed that statistically significant differences could be attained with smaller groups if lung virus titers were measured, since drug treatment delayed but did not completely prevent mortality (<xref ref-type="supplementary-material" rid="SM1">Supplemental Figure 1</xref>). Toward this, animals were infected intranasally with 10<sup>3</sup> TCID<sub>50</sub> PR8, sacrificed 3 days post-infection, and the viral load in the lung was quantified. Oseltamivir phosphate was most effective, reducing lung titers 28-fold, followed by dextromethorphan, which resulted in a more variable but significant reduction. Ketotifen was less effective, but still lowered lung viral titers around 8- to 10-fold, while naltrexone and gallium nitrate treatments had no significant effect (<xref ref-type="fig" rid="F3">Figure 3A</xref>).</p><fig id="F3" position="float"><label>Figure 3</label><caption><p>Inhibitory effect of drug candidates in mice. C57BL/6 mice were treated orally once daily starting 1 day before infection and continuing until sacrifice with the respective drug at the maximum tolerated dose individually <bold>(A)</bold> or in combination <bold>(B)</bold>. The animals were infected intranasally with 10<sup>3</sup> TCID<sub>50</sub> of PR8. Three days post-infection, the animals were sacrificed and the lung titers were quantified by limited dilution method and expressed as TCID<sub>50</sub>/g tissue. Bars indicate group means, and the dotted line reflects the detection limit of the assay. One-way analysis of variance (ANOVA) with Dunnett's Multiple Comparison Test was used for statistical analyses (no significance (n.s.), <sup>*</sup><italic>p</italic> &#x0003c; 0.05, <sup>**</sup><italic>p</italic> &#x0003c; 0.01, <sup>***</sup><italic>p</italic> &#x0003c; 0.001).</p></caption><graphic xlink:href="fimmu-10-01097-g0003"/></fig><p>As a &#x003c3;<sub>1</sub>-receptor agonist, dextromethorphan targets a different cellular pathway than ketotifen, which is a histamine H1 receptor blocker (<xref rid="B36" ref-type="bibr">36</xref>, <xref rid="B42" ref-type="bibr">42</xref>). To evaluate potential additive effects of the two drugs and oseltamivir, mice were again treated orally once daily with the respective drug combinations, starting again 1 day before infection. In this series of experiments, the inhibitory effect of ketotifen alone was even less pronounced, and there was no additive effect when ketotifen and dextromethorphan were combined. Combination of each of the drugs with oseltamivir resulted in a slight, but non-significant increase in inhibition, but when all three drugs were combined, the inhibitory effect was significantly higher than that of oseltamivir alone (<xref ref-type="fig" rid="F3">Figure 3B</xref>), suggesting a modest benefit of combination treatment in this context.</p></sec><sec><title>Dextromethorphan Has no Effect on Viral Load but Reduces Clinical Disease in Ferrets</title><p>To assess the therapeutic potential of dextromethorphan in an animal model that reproduces the course of disease seen in humans (<xref rid="B43" ref-type="bibr">43</xref>, <xref rid="B44" ref-type="bibr">44</xref>), ferrets were treated every 8 h with either commercially available oral dextromethorphan formulation at a dose of 2 mg/kg, or oseltamivir solution at a dose of 2.5 mg/kg. This schedule was in accordance with the recommendation for dextromethorphan treatment of patients, and the doses were within the weight adjusted human dose range. Drugs were given for the first time 24 h prior to infection and treatment was continued for 5 days. Nasal washes were collected daily, and the animals were evaluated twice daily for weight loss, temperature, and clinical signs.</p><p>While oseltamivir phosphate treatment resulted in a 10-fold reduction in nasal wash titers during the first 2 days, dextromethorphan had no effect (<xref ref-type="fig" rid="F4">Figure 4A</xref>), and none of the treatment approaches affected lung viral titers in animals sacrificed on day 3 (data not shown). In all three groups, the titers peaked on day 2 post-infection and then gradually decreased (<xref ref-type="fig" rid="F4">Figure 4A</xref>). Dextromethorphan-treated animals also experienced a similar gradual weight loss of &#x0003c;10% seen in non-treated control animals, whereas there was no reduction in body weight in the oseltamivir group (<xref ref-type="fig" rid="F4">Figure 4B</xref>). In the control group, clinical signs and fever became first apparent 36 h post-infection, peaked after 48 h, and then gradually decreased (<xref ref-type="fig" rid="F4">Figure 4C</xref>). Dextromethorphan treatment resulted in a significantly lower peak score (<xref ref-type="fig" rid="F4">Figure 4C</xref>). Even though the effect was less pronounced compared to oseltamivir phosphate treatment, which only resulted in a minimal clinical score peaking on day 3 (<xref ref-type="fig" rid="F4">Figure 4C</xref>), it illustrates the potential of repurposing drugs targeting cellular factors involved in the viral life cycle.</p><fig id="F4" position="float"><label>Figure 4</label><caption><p>Dextromethorphan efficacy assessment in ferrets. Ferrets (<italic>n</italic> = 9) were treated orally every 8 h for 5 days or until sacrifice on day 3 (<italic>n</italic> = 4), starting 1 day before infection with 2 mg/kg dextromethorphan or 2.5 mg/kg oseltamivir, corresponding to recommended human doses. The animals were infected intranasally with 10<sup>5</sup> TCID<sub>50</sub> of A/Mexico/InDRE4487/2009. <bold>(A)</bold> Nasal washes were collected daily, and titers were quantified by limited dilution method. For the first 4 days, animals were monitored twice daily and daily thereafter for weight <bold>(B)</bold> and clinical signs <bold>(C)</bold>. The clinical score represents a composite score of body temperature, activity, nasal exudate, and respiratory signs scored on a 0-1-2 scale with 0 representing body temperatures &#x02264;39.3&#x000b0;C and the physiologic state, 1 temperatures 39.4&#x02013;39.9&#x000b0;C, calm behavior, low amounts of clear exudate, and occasional sneezing or congestion, and 2 temperatures &#x02265;40.0&#x000b0;C, depressed behavior, larger amounts of yellow or brown exudate, and frequent sneezing, coughing and/or dyspnea. Symbols represent group averages, and error bars indicate the standard error mean. One-way analysis of variance (ANOVA) with Tukey's Multiple Comparison Test was used for statistical analyses (<sup>***</sup><italic>p</italic> &#x0003c; 0.001).</p></caption><graphic xlink:href="fimmu-10-01097-g0004"/></fig></sec></sec><sec sec-type="discussion" id="s4"><title>Discussion</title><p>Antiviral approaches targeting cellular proteins or pathways involved in the viral life cycle rather than viral proteins directly have great appeal as they are thought to be less prone to resistance development and may be effective against different strains and even different virus families (<xref rid="B16" ref-type="bibr">16</xref>, <xref rid="B45" ref-type="bibr">45</xref>). For influenza virus, several whole genome siRNA screens have been published in recent years (<xref rid="B18" ref-type="bibr">18</xref>&#x02013;<xref rid="B21" ref-type="bibr">21</xref>), allowing the cross-matching of host proteins required for influenza replication with known cellular drug targets. Using this approach, we identified a short list of 15 FDA-approved candidate drugs, of which naltrexone, gallium nitrate, ketotifen, and dextromethorphan were able to inhibit viral replication <italic>in vitro</italic> in a dose-dependent manner. Successive <italic>in vivo</italic> evaluation in mice revealed that dextromethorphan was the most promising candidate. Dextromethorphan treatment of ferrets infected with a H1N1pdm09 strain had no effect on viral load or body weight, but resulted in a significant reduction of clinical signs, supporting its further consideration as an influenza treatment option.</p><p>High-throughput siRNA screens have opened a new avenue for drug repurposing (<xref rid="B46" ref-type="bibr">46</xref>). This is of special relevance for infectious disease targets with lesser market potential, as the development of new drugs is time consuming and costly (<xref rid="B47" ref-type="bibr">47</xref>, <xref rid="B48" ref-type="bibr">48</xref>). The severe side effects associated with the chemotherapeutics and immune modulators often found among the top hits may not be acceptable in the context of the target disease, so they are usually not evaluated any further. <italic>In vitro</italic> efficacy assessments of the remaining hits are amenable to medium or high throughput screening, allowing a rapid identification of the most promising candidates (<xref rid="B49" ref-type="bibr">49</xref>). Here we show that an <italic>in vivo</italic> efficacy assessment of such candidates is warranted even if the EC<sub>50</sub> is in the &#x003bc;M range and the SI is consequently low, especially if the drug has a broad therapeutic range, as they may be attractive options for treatment in combination with antivirals or other drugs targeting complementary cellular pathways involved in the viral life cycle.</p><p>Two of the identified drugs, ketotifen, and dextromethorphan, not only led to a reduction of viral titers <italic>in vitro</italic>, but also in mice. While ketotifen blocks histamine H1 receptors and the release of inflammatory mediators, and is used to treat asthma, rhinitis, skin allergies, and anaphylaxis (<xref rid="B36" ref-type="bibr">36</xref>, <xref rid="B50" ref-type="bibr">50</xref>), dextromethorphan is primarily a &#x003c3;<sub>1</sub>-receptor agonist and used as an alternative to opioid-containing cough suppressants (<xref rid="B51" ref-type="bibr">51</xref>, <xref rid="B52" ref-type="bibr">52</xref>). The antiviral properties of ketotifen may thus be associated with its anti-inflammatory effect (<xref rid="B39" ref-type="bibr">39</xref>), which could be substantiated by comparatively quantifying the release of inflammatory mediators in ketotifen- and untreated infected cells or animals. In contrast, the mechanism of action is less obvious for dextromethorphan. Its target, the &#x003c3;<sub>1</sub>-receptor, is a chaperone located at the mitochondria-associated endoplasmic reticulum (ER) membrane (<xref rid="B53" ref-type="bibr">53</xref>). The protein plays an important role in cell homeostasis, since its knock down leads to ER stress, induction of the unfolded-protein response (UPR), dysfunctional autophagosomes, and oxidative stress (<xref rid="B54" ref-type="bibr">54</xref>&#x02013;<xref rid="B56" ref-type="bibr">56</xref>), and it also modulates Ca<sup>2+</sup> release through the interaction with inositol 1,4,5-phosphate receptors (IP3R) (<xref rid="B57" ref-type="bibr">57</xref>). This modulation may underlie the anti-influenza effect of dextromethorphan, since viral transcription and replication require Ca<sup>2+</sup> action through calmodulin (<xref rid="B20" ref-type="bibr">20</xref>, <xref rid="B58" ref-type="bibr">58</xref>), and Ca<sup>2+</sup> is also involved in viral entry through the regulation of clathrin-mediated and clathrin-independent endocytosis (<xref rid="B59" ref-type="bibr">59</xref>). If the primary mode of action of dextromethorphan-mediated &#x003c3;<sub>1</sub>-receptor signaling inhibition lies in such a direct inhibition of viral entry or replication, or rather in the modulation of innate immune responses (<xref rid="B34" ref-type="bibr">34</xref>) is the subject of ongoing studies.</p><p>Ferrets closely mimic the course of influenza disease seen in humans (<xref rid="B44" ref-type="bibr">44</xref>, <xref rid="B60" ref-type="bibr">60</xref>). Seasonal and pandemic 2009 influenza viruses thus cause a mild to moderate disease of 3&#x02013;5 days duration (<xref rid="B23" ref-type="bibr">23</xref>, <xref rid="B61" ref-type="bibr">61</xref>), making it challenging to discern modest differences in disease severity and pathological and virological parameters. While oseltamivir reduced viral load and clinical disease, and prevented weight loss, dextromethorphan treatment only reduced disease severity, and seemed to slightly increase the weight loss compared to untreated animals. However, this seemingly small effect may make the difference between seeking medical attention or just staying at home, and may also reduce the days of lost productivity during the annual epidemics. Future studies are warranted to evaluate if combination treatment increases the efficacy of oseltamivir or other virus-targeting drugs, especially when treatment is started after the onset of clinical disease. There may also be room for short-term treatment at higher doses, given that the dosing regimen used here did not exceed recommended human weight-adjusted doses. Considering that dextromethorphan-containing drugs are frequently used as over the counter remedies for influenza and influenza-like respiratory infections, a more detailed evaluation of its efficacy, especially in combination with other influenza-specific drugs, would be warranted.</p></sec><sec id="s5"><title>Ethics Statement</title><p>This study was carried out in accordance with the recommendations of the SingHealth IACUC committee or the county experimental animal oversight agency (Regierungspraesidium Darmstadt), respectively.</p></sec><sec id="s6"><title>Author Contributions</title><p>TE performed most of the experiments. TE and VvM conceived the study, analyzed, and interpreted data, and wrote the manuscript. EG and DA designed and conducted the initial screening experiments. SS assisted with the <italic>in vitro</italic> and animal studies validating the top hits. DK and SM-S performed the bioinformatics analyses and wrote part of the manuscript.</p><sec><title>Conflict of Interest Statement</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec></sec></body><back><ack><p>We thank all laboratory members for continuing support and lively discussions and Yvonne Krebs for excellent technical support. We would like to acknowledge Eugene Lim and Anne Baumg&#x000e4;rtner for assistance with the titration experiments, Raphael Tze Chuen Lee for help with the co-expression, and Hong Sain Ooi for the protein-protein interaction data.</p></ack><fn-group><fn fn-type="financial-disclosure"><p><bold>Funding.</bold> This work was supported in part by funding from the German Center for Infection Research, the German Ministry of Health, and a DUKE-NUS Signature Research Program start-up grant funded by the Agency for Science, Technology, and Research (A<sup>*</sup>STAR), Singapore and the Ministry of Health, Singapore to VvM, and A<sup>*</sup>STAR grant H1699f0013 to SM-S.</p></fn></fn-group><sec sec-type="supplementary-material" id="s7"><title>Supplementary Material</title><p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fimmu.2019.01097/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fimmu.2019.01097/full#supplementary-material</ext-link></p><supplementary-material content-type="local-data" id="SM1"><media xlink:href="Image_1.JPEG"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec><ref-list><title>References</title><ref id="B1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kilbourne</surname><given-names>ED</given-names></name></person-group>. <article-title>Influenza pandemics of the 20th century</article-title>. <source>Emerg Infect Dis.</source> (<year>2006</year>) <volume>12</volume>:<fpage>9</fpage>&#x02013;<lpage>14</lpage>. <pub-id pub-id-type="doi">10.3201/eid1201.051254</pub-id><?supplied-pmid 16494710?><pub-id pub-id-type="pmid">16494710</pub-id></mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Osterhaus</surname><given-names>A</given-names></name><name><surname>Brooks</surname><given-names>A</given-names></name><name><surname>Broberg</surname><given-names>E</given-names></name><name><surname>MacIntyre</surname><given-names>R</given-names></name><name><surname>Capua</surname><given-names>I</given-names></name></person-group>. <article-title>Why should influenza be a public health priority</article-title>. <source>Vaccine.</source> (<year>2015</year>) <volume>33</volume>:<fpage>7022</fpage>&#x02013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2015.08.049</pub-id><?supplied-pmid 26319062?><pub-id pub-id-type="pmid">26319062</pub-id></mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Shaw</surname><given-names>ML</given-names></name><name><surname>Palese</surname><given-names>P</given-names></name></person-group>
<article-title>Orthomyxoviridae</article-title>. In: <person-group person-group-type="editor"><name><surname>Knipe</surname><given-names>DM</given-names></name><name><surname>Howley</surname><given-names>PM</given-names></name></person-group> editors. <source>Fields Virology</source>. <publisher-loc>Philadelphia, PA</publisher-loc>: <publisher-name>Lippincott Williams &#x00026; Wilkins</publisher-name> (<year>2013</year>). p. <fpage>1151</fpage>&#x02013;<lpage>85</lpage>.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mehle</surname><given-names>A</given-names></name></person-group>. <article-title>Unusual influenza A viruses in bats</article-title>. <source>Viruses.</source> (<year>2014</year>) <volume>6</volume>:<fpage>3438</fpage>&#x02013;<lpage>49</lpage>. <pub-id pub-id-type="doi">10.3390/v6093438</pub-id><?supplied-pmid 25256392?><pub-id pub-id-type="pmid">25256392</pub-id></mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neumann</surname><given-names>G</given-names></name><name><surname>Kawaoka</surname><given-names>Y</given-names></name></person-group>
<article-title>Transmission of influenza A viruses</article-title>. <source>Virology.</source> (<year>2015</year>) <volume>479&#x02013;80</volume>:<fpage>234</fpage>&#x02013;<lpage>246</lpage>. <pub-id pub-id-type="doi">10.1016/j.virol.2015.03.009</pub-id></mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalthoff</surname><given-names>D</given-names></name><name><surname>Globig</surname><given-names>A</given-names></name><name><surname>Beer</surname><given-names>M</given-names></name></person-group>. <article-title>Highly pathogenic avian influenza as a zoonotic agent</article-title>. <source>Vet Microbiol.</source> (<year>2010</year>) <volume>140</volume>:<fpage>237</fpage>&#x02013;<lpage>45</lpage>. <pub-id pub-id-type="doi">10.1016/j.vetmic.2009.08.022</pub-id><?supplied-pmid 19782482?><pub-id pub-id-type="pmid">19782482</pub-id></mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perdue</surname><given-names>ML</given-names></name><name><surname>Swayne</surname><given-names>DE</given-names></name></person-group>. <article-title>Public health risk from avian influenza viruses</article-title>. <source>Avian Dis.</source> (<year>2005</year>) <volume>49</volume>:<fpage>317</fpage>&#x02013;<lpage>27</lpage>. <pub-id pub-id-type="doi">10.1637/7390-060305R.1</pub-id><?supplied-pmid 16252482?><pub-id pub-id-type="pmid">16252482</pub-id></mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Xue</surname><given-names>M</given-names></name><name><surname>Xue</surname><given-names>M</given-names></name><name><surname>Wu</surname><given-names>C</given-names></name><name><surname>Lu</surname><given-names>Q</given-names></name><etal/></person-group>. <article-title>Spatial characteristics and the epidemiology of human infections with avian influenza A(H7N9) virus in five waves from 2013 to 2017 in Zhejiang Province, China</article-title>. <source>PLoS One</source>. (<year>2017</year>) <volume>12</volume>:<fpage>e0180763</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0180763</pub-id><?supplied-pmid 28750032?><pub-id pub-id-type="pmid">28750032</pub-id></mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nafziger</surname><given-names>AN</given-names></name><name><surname>Pratt</surname><given-names>DS</given-names></name></person-group>. <article-title>Seasonal influenza vaccination and technologies</article-title>. <source>J Clin Pharmacol.</source> (<year>2014</year>) <volume>54</volume>:<fpage>719</fpage>&#x02013;<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1002/jcph.299</pub-id><?supplied-pmid 24691877?><pub-id pub-id-type="pmid">24691877</pub-id></mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Intharathep</surname><given-names>P</given-names></name><name><surname>Laohpongspaisan</surname><given-names>C</given-names></name><name><surname>Rungrotmongkol</surname><given-names>T</given-names></name><name><surname>Loisruangsin</surname><given-names>A</given-names></name><name><surname>Malaisree</surname><given-names>M</given-names></name><name><surname>Decha</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>How amantadine and rimantadine inhibit proton transport in the M2 protein channel</article-title>. <source>J Mol Graph Model.</source> (<year>2008</year>) <volume>27</volume>:<fpage>342</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.jmgm.2008.06.002</pub-id><?supplied-pmid 18620883?><pub-id pub-id-type="pmid">18620883</pub-id></mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamali</surname><given-names>A</given-names></name><name><surname>Holodniy</surname><given-names>M</given-names></name></person-group>. <article-title>Influenza treatment and prophylaxis with neuraminidase inhibitors: a review</article-title>. <source>Infect Drug Resist.</source> (<year>2013</year>) <volume>6</volume>:<fpage>187</fpage>&#x02013;<lpage>98</lpage>. <pub-id pub-id-type="doi">10.2147/IDR.S36601</pub-id><?supplied-pmid 24277988?><pub-id pub-id-type="pmid">24277988</pub-id></mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deyde</surname><given-names>VM</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Bright</surname><given-names>RA</given-names></name><name><surname>Shaw</surname><given-names>M</given-names></name><name><surname>Smith</surname><given-names>CB</given-names></name><etal/></person-group>. <article-title>Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide</article-title>. <source>J Infect Dis.</source> (<year>2007</year>) <volume>196</volume>:<fpage>249</fpage>&#x02013;<lpage>57</lpage>. <pub-id pub-id-type="doi">10.1086/518936</pub-id><?supplied-pmid 17570112?><pub-id pub-id-type="pmid">17570112</pub-id></mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gubareva</surname><given-names>LV</given-names></name><name><surname>Besselaar</surname><given-names>TG</given-names></name><name><surname>Daniels</surname><given-names>RS</given-names></name><name><surname>Fry</surname><given-names>A</given-names></name><name><surname>Gregory</surname><given-names>V</given-names></name><name><surname>Huang</surname><given-names>W</given-names></name><etal/></person-group>. <article-title>Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2015&#x02013;2016</article-title>. <source>Antiviral Res.</source> (<year>2017</year>) <volume>146</volume>:<fpage>12</fpage>&#x02013;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2017.08.004</pub-id><?supplied-pmid 28802866?><pub-id pub-id-type="pmid">28802866</pub-id></mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heo</surname><given-names>YA</given-names></name></person-group>. <article-title>Baloxavir: First global approval</article-title>. <source>Drugs</source>. (<year>2018</year>) <volume>78</volume>:<fpage>693</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1007/s40265-018-0899-1</pub-id><?supplied-pmid 29623652?><pub-id pub-id-type="pmid">29623652</pub-id></mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koszalka</surname><given-names>P</given-names></name><name><surname>Tilmanis</surname><given-names>D</given-names></name><name><surname>Hurt</surname><given-names>AC</given-names></name></person-group>. <article-title>Influenza antivirals currently in late-phase clinical trial</article-title>. <source>Influenza Other Respir Viruses</source>. (<year>2017</year>) <volume>11</volume>:<fpage>240</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1111/irv.12446</pub-id><?supplied-pmid 28146320?><pub-id pub-id-type="pmid">28146320</pub-id></mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Chassey</surname><given-names>B</given-names></name><name><surname>Meyniel-Schicklin</surname><given-names>L</given-names></name><name><surname>Vonderscher</surname><given-names>J</given-names></name><name><surname>Andr&#x000e9;</surname><given-names>P</given-names></name><name><surname>Lotteau</surname><given-names>V</given-names></name></person-group>
<article-title>Virus-host interactomics: new insights and opportunities for antiviral drug discovery</article-title>. <source>Genome Med.</source>
<volume>6</volume>:<fpage>115</fpage>
<pub-id pub-id-type="doi">10.1186/s13073-014-0115-1</pub-id></mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Law</surname><given-names>GL</given-names></name><name><surname>Korth</surname><given-names>MJ</given-names></name><name><surname>Benecke</surname><given-names>AG</given-names></name><name><surname>Katze</surname><given-names>MG</given-names></name></person-group>. <article-title>Systems virology: host-directed approaches to viral pathogenesis and drug targeting</article-title>. <source>Nat Rev Microbiol.</source> (<year>2013</year>) <volume>11</volume>:<fpage>455</fpage>&#x02013;<lpage>66</lpage>. <pub-id pub-id-type="doi">10.1038/nrmicro3036</pub-id><?supplied-pmid 23728212?><pub-id pub-id-type="pmid">23728212</pub-id></mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brass</surname><given-names>AL</given-names></name><name><surname>Huang</surname><given-names>IC</given-names></name><name><surname>Benita</surname><given-names>Y</given-names></name><name><surname>John</surname><given-names>SP</given-names></name><name><surname>Krishnan</surname><given-names>MN</given-names></name><name><surname>Feeley</surname><given-names>EM</given-names></name><etal/></person-group>. <article-title>The IFITM proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus, and dengue virus</article-title>. <source>Cell.</source> (<year>2009</year>) <volume>139</volume>:<fpage>1243</fpage>&#x02013;<lpage>54</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2009.12.017</pub-id><?supplied-pmid 20064371?><pub-id pub-id-type="pmid">20064371</pub-id></mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karlas</surname><given-names>A</given-names></name><name><surname>Machuy</surname><given-names>N</given-names></name><name><surname>Shin</surname><given-names>Y</given-names></name><name><surname>Pleissner</surname><given-names>KP</given-names></name><name><surname>Artarini</surname><given-names>A</given-names></name><name><surname>Heuer</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Genome-wide RNAi screen identifies human host factors crucial for influenza virus replication</article-title>. <source>Nature.</source> (<year>2010</year>) <volume>463</volume>:<fpage>818</fpage>&#x02013;<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1038/nature08760</pub-id><?supplied-pmid 20081832?><pub-id pub-id-type="pmid">20081832</pub-id></mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>K&#x000f6;nig</surname><given-names>R</given-names></name><name><surname>Stertz</surname><given-names>S</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Inoue</surname><given-names>A</given-names></name><name><surname>Hoffmann</surname><given-names>HH</given-names></name><name><surname>Bhattacharyya</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Human host factors required for influenza virus replication</article-title>. <source>Nature.</source> (<year>2010</year>) <volume>463</volume>:<fpage>813</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1038/nature08699</pub-id><?supplied-pmid 20027183?><pub-id pub-id-type="pmid">20027183</pub-id></mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shapira</surname><given-names>SD</given-names></name><name><surname>Gat-Viks</surname><given-names>I</given-names></name><name><surname>Shum</surname><given-names>BO</given-names></name><name><surname>Dricot</surname><given-names>A</given-names></name><name><surname>de Grace</surname><given-names>MM</given-names></name><name><surname>Wu</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>A physical and regulatory map of host-influenza interactions reveals pathways in H1N1 infection</article-title>. <source>Cell.</source> (<year>2009</year>) <volume>139</volume>:<fpage>1255</fpage>&#x02013;<lpage>67</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2009.12.018</pub-id><?supplied-pmid 20064372?><pub-id pub-id-type="pmid">20064372</pub-id></mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watanabe</surname><given-names>T</given-names></name><name><surname>Watanabe</surname><given-names>S</given-names></name><name><surname>Kawaoka</surname><given-names>Y</given-names></name></person-group>. <article-title>Cellular networks involved in the influenza virus life cycle</article-title>. <source>Cell Host Microbe.</source> (<year>2010</year>) <volume>7</volume>:<fpage>427</fpage>&#x02013;<lpage>39</lpage>. <pub-id pub-id-type="doi">10.1016/j.chom.2010.05.008</pub-id><?supplied-pmid 20542247?><pub-id pub-id-type="pmid">20542247</pub-id></mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Svitek</surname><given-names>N</given-names></name><name><surname>Rudd</surname><given-names>PA</given-names></name><name><surname>Obojes</surname><given-names>K</given-names></name><name><surname>Pillet</surname><given-names>S</given-names></name><name><surname>von Messling</surname><given-names>V</given-names></name></person-group>. <article-title>Severe seasonal influenza in ferrets correlates with reduced interferon and increased IL-6 induction</article-title>. <source>Virology.</source> (<year>2008</year>) <volume>376</volume>:<fpage>53</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.virol.2008.02.035</pub-id><?supplied-pmid 18420248?><pub-id pub-id-type="pmid">18420248</pub-id></mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kobinger</surname><given-names>GP</given-names></name><name><surname>Meunier</surname><given-names>I</given-names></name><name><surname>Patel</surname><given-names>A</given-names></name><name><surname>Pillet</surname><given-names>S</given-names></name><name><surname>Gren</surname><given-names>J</given-names></name><name><surname>Stebner</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Assessment of the efficacy of commercially available and candidate vaccines against a pandemic H1N1 2009 virus</article-title>. <source>J Infect Dis.</source> (<year>2010</year>) <volume>201</volume>:<fpage>1000</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1086/651171</pub-id><?supplied-pmid 20170374?><pub-id pub-id-type="pmid">20170374</pub-id></mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barrett</surname><given-names>T</given-names></name><name><surname>Troup</surname><given-names>DB</given-names></name><name><surname>Wilhite</surname><given-names>SE</given-names></name><name><surname>Ledoux</surname><given-names>P</given-names></name><name><surname>Rudnev</surname><given-names>D</given-names></name><name><surname>Evangelista</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>NCBI GEO: mining tens of millions of expression profiles&#x02013;database and tools update</article-title>. <source>Nucleic Acids Res.</source> (<year>2007</year>) <volume>35</volume>:<fpage>D760</fpage>&#x02013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkl887</pub-id><?supplied-pmid 17099226?><pub-id pub-id-type="pmid">17099226</pub-id></mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ooi</surname><given-names>HS</given-names></name><name><surname>Schneider</surname><given-names>G</given-names></name><name><surname>Chan</surname><given-names>YL</given-names></name><name><surname>Lim</surname><given-names>TT</given-names></name><name><surname>Eisenhaber</surname><given-names>B</given-names></name><name><surname>Eisenhaber</surname><given-names>F</given-names></name></person-group>. <article-title>Databases of protein-protein interactions and complexes</article-title>. <source>Methods Mol Biol.</source> (<year>2010</year>) <volume>609</volume>:<fpage>145</fpage>&#x02013;<lpage>59</lpage>. <pub-id pub-id-type="doi">10.1007/978-1-60327-241-4_9</pub-id><?supplied-pmid 20221918?><pub-id pub-id-type="pmid">20221918</pub-id></mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knox</surname><given-names>C</given-names></name><name><surname>Law</surname><given-names>V</given-names></name><name><surname>Jewison</surname><given-names>T</given-names></name><name><surname>Liu</surname><given-names>P</given-names></name><name><surname>Ly</surname><given-names>S</given-names></name><name><surname>Frolkis</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>DrugBank 3.0: a comprehensive resource for &#x0201c;omics&#x0201d; research on drugs</article-title>. <source>Nucleic Acids Res.</source> (<year>2011</year>) <volume>39</volume>:<fpage>D1035</fpage>&#x02013;<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkq1126</pub-id><?supplied-pmid 21059682?><pub-id pub-id-type="pmid">21059682</pub-id></mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sleeman</surname><given-names>K</given-names></name><name><surname>Mishin</surname><given-names>VP</given-names></name><name><surname>Deyde</surname><given-names>VM</given-names></name><name><surname>Furuta</surname><given-names>Y</given-names></name><name><surname>Klimov</surname><given-names>AI</given-names></name><name><surname>Gubareva</surname><given-names>LV</given-names></name></person-group>. <article-title><italic>In vitro</italic> antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses</article-title>. <source>Antimicrobial Agents Chemother.</source> (<year>2010</year>) <volume>54</volume>:<fpage>2517</fpage>&#x02013;<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1128/AAC.01739-09</pub-id><?supplied-pmid 20350949?><pub-id pub-id-type="pmid">20350949</pub-id></mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tomie</surname><given-names>A</given-names></name><name><surname>Azogu</surname><given-names>I</given-names></name><name><surname>Yu</surname><given-names>L</given-names></name></person-group>. <article-title>Effects of naltrexone on post-abstinence alcohol drinking in C57BL/6NCRL and DBA/2J mice</article-title>. <source>Prog Neuropsychopharmacol Biol Psychiatry.</source> (<year>2013</year>) <volume>44</volume>:<fpage>240</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/j.pnpbp.2013.03.002</pub-id><?supplied-pmid 23499782?><pub-id pub-id-type="pmid">23499782</pub-id></mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Apseloff</surname><given-names>G</given-names></name></person-group>. <article-title>Therapeutic uses of gallium nitrate: past, present, and future</article-title>. <source>Am J Ther.</source> (<year>1999</year>) <volume>6</volume>:<fpage>327</fpage>&#x02013;<lpage>39</lpage>.<?supplied-pmid 11329118?><pub-id pub-id-type="pmid">11329118</pub-id></mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bockman</surname><given-names>R</given-names></name></person-group>. <article-title>The effects of gallium nitrate on bone resorption</article-title>. <source>Semin Oncol.</source> (<year>2003</year>) <volume>30</volume>(2 <issue>Suppl. 5</issue>):<fpage>5</fpage>&#x02013;<lpage>12</lpage>.<?supplied-pmid 12776254?><pub-id pub-id-type="pmid">12776254</pub-id></mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamauchi</surname><given-names>Y</given-names></name><name><surname>Boukari</surname><given-names>H</given-names></name><name><surname>Banerjee</surname><given-names>I</given-names></name><name><surname>Sbalzarini</surname><given-names>IF</given-names></name><name><surname>Horvath</surname><given-names>P</given-names></name><name><surname>Helenius</surname><given-names>A</given-names></name></person-group>. <article-title>Histone deacetylase 8 is required for centrosome cohesion and influenza A virus entry</article-title>. <source>PLoS Pathog.</source> (<year>2011</year>) <volume>7</volume>:<fpage>e1002316</fpage>. <pub-id pub-id-type="doi">10.1371/journal.ppat.1002316</pub-id><?supplied-pmid 22046129?><pub-id pub-id-type="pmid">22046129</pub-id></mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>TP</given-names></name><name><surname>Su</surname><given-names>TC</given-names></name><name><surname>Nakamura</surname><given-names>Y</given-names></name><name><surname>Tsai</surname><given-names>SY</given-names></name></person-group>. <article-title>The Sigma-1 Receptor as a Pluripotent Modulator in Living Systems</article-title>. <source>Trends Pharmacol Sci.</source> (<year>2016</year>) <volume>37</volume>:<fpage>262</fpage>&#x02013;<lpage>78</lpage>. <pub-id pub-id-type="doi">10.1016/j.tips.2016.01.003</pub-id><?supplied-pmid 26869505?><pub-id pub-id-type="pmid">26869505</pub-id></mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>WR</given-names></name><name><surname>Eades</surname><given-names>CG</given-names></name><name><surname>Thompson</surname><given-names>JA</given-names></name><name><surname>Huppler</surname><given-names>RE</given-names></name><name><surname>Gilbert</surname><given-names>PE</given-names></name></person-group>. <article-title>The effects of morphine- and nalorphine- like drugs in the nondependent and morphine-dependent chronic spinal dog</article-title>. <source>J Pharmacol Exp Ther.</source> (<year>1976</year>) <volume>197</volume>:<fpage>517</fpage>&#x02013;<lpage>32</lpage>.<?supplied-pmid 945347?><pub-id pub-id-type="pmid">945347</pub-id></mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szabo</surname><given-names>A</given-names></name><name><surname>Kovacs</surname><given-names>A</given-names></name><name><surname>Frecska</surname><given-names>E</given-names></name><name><surname>Rajnavolgyi</surname><given-names>E</given-names></name></person-group>. <article-title>Psychedelic N,N-dimethyltryptamine and 5-methoxy-N,N-dimethyltryptamine modulate innate and adaptive inflammatory responses through the sigma-1 receptor of human monocyte-derived dendritic cells</article-title>. <source>PLoS One</source>. (<year>2014</year>) <volume>9</volume>:<fpage>e106533</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0106533</pub-id><?supplied-pmid 25171370?><pub-id pub-id-type="pmid">25171370</pub-id></mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bielory</surname><given-names>L</given-names></name><name><surname>Lien</surname><given-names>KW</given-names></name><name><surname>Bigelsen</surname><given-names>S</given-names></name></person-group>. <article-title>Efficacy and tolerability of newer antihistamines in the treatment of allergic conjunctivitis</article-title>. <source>Drugs.</source> (<year>2005</year>) <volume>65</volume>:<fpage>215</fpage>&#x02013;<lpage>28</lpage>. <pub-id pub-id-type="doi">10.2165/00003495-200565020-00004</pub-id><?supplied-pmid 15631542?><pub-id pub-id-type="pmid">15631542</pub-id></mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akkemik</surname><given-names>E</given-names></name><name><surname>Budak</surname><given-names>H</given-names></name><name><surname>Ciftci</surname><given-names>M</given-names></name></person-group>. <article-title>Effects of some drugs on human erythrocyte glucose 6-phosphate dehydrogenase: an <italic>in vitro</italic> study</article-title>. <source>J Enzyme Inhib Med Chem.</source> (<year>2010</year>) <volume>25</volume>:<fpage>871</fpage>&#x02013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.3109/14756360903489581</pub-id><?supplied-pmid 21054237?><pub-id pub-id-type="pmid">21054237</pub-id></mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Janke</surname><given-names>R</given-names></name><name><surname>Genzel</surname><given-names>Y</given-names></name><name><surname>Wetzel</surname><given-names>M</given-names></name><name><surname>Reichl</surname><given-names>U</given-names></name></person-group>. <article-title>Effect of influenza virus infection on key metabolic enzyme activities in MDCK cells</article-title>. <source>BMC Proc.</source> (<year>2011</year>) <volume>5</volume>(<issue>Suppl. 8</issue>):P<fpage>129</fpage>. <pub-id pub-id-type="doi">10.1186/1753-6561-5-S8-P129</pub-id><?supplied-pmid 22373286?><pub-id pub-id-type="pmid">22373286</pub-id></mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Jin</surname><given-names>Y</given-names></name><name><surname>Han</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>G</given-names></name><name><surname>Cao</surname><given-names>S</given-names></name><name><surname>Xie</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Mast cell-induced lung injury in mice infected with H5N1 influenza virus</article-title>. <source>J Virol.</source> (<year>2012</year>) <volume>86</volume>:<fpage>3347</fpage>&#x02013;<lpage>56</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.06053-11</pub-id><?supplied-pmid 22238293?><pub-id pub-id-type="pmid">22238293</pub-id></mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>SL Li YH</given-names></name><name><surname>Shi</surname><given-names>GY</given-names></name><name><surname>Tang</surname><given-names>SH</given-names></name><name><surname>Jiang</surname><given-names>SJ</given-names></name><name><surname>Huang</surname><given-names>CW</given-names></name><name><surname>Liu</surname><given-names>PY</given-names></name><etal/></person-group>. <article-title>Dextromethorphan reduces oxidative stress and inhibits atherosclerosis and neointima formation in mice</article-title>. <source>Cardiovasc Res.</source> (<year>2009</year>) <volume>82</volume>:<fpage>161</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1093/cvr/cvp043</pub-id><?supplied-pmid 19189960?><pub-id pub-id-type="pmid">19189960</pub-id></mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smee</surname><given-names>DF</given-names></name><name><surname>Hurst</surname><given-names>BL</given-names></name><name><surname>Wong</surname><given-names>MH</given-names></name><name><surname>Bailey</surname><given-names>KW</given-names></name><name><surname>Morrey</surname><given-names>JD</given-names></name></person-group>. <article-title>Effects of double combinations of amantadine, oseltamivir, and ribavirin on influenza A (H5N1) virus infections in cell culture and in mice</article-title>. <source>Antimicrob Agents Chemother.</source> (<year>2009</year>) <volume>53</volume>:<fpage>2120</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1128/AAC.01012-08</pub-id><?supplied-pmid 19273672?><pub-id pub-id-type="pmid">19273672</pub-id></mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>L</given-names></name><name><surname>Robson</surname><given-names>MJ</given-names></name><name><surname>Healy</surname><given-names>JR</given-names></name><name><surname>Scandinaro</surname><given-names>AL</given-names></name><name><surname>Matsumoto</surname><given-names>RR</given-names></name></person-group>. <article-title>Involvement of sigma-1 receptors in the antidepressant-like effects of dextromethorphan</article-title>. <source>PLoS ONE.</source>
<volume>9</volume>:<fpage>e89985</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0089985</pub-id><?supplied-pmid 24587167?><pub-id pub-id-type="pmid">24587167</pub-id></mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bouvier</surname><given-names>NM</given-names></name></person-group>. <article-title>Animal models for influenza virus transmission studies: a historical perspective</article-title>. <source>Curr Opin Virol.</source> (<year>2015</year>) <volume>13</volume>:<fpage>101</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.coviro.2015.06.002</pub-id><?supplied-pmid 26126082?><pub-id pub-id-type="pmid">26126082</pub-id></mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Enkirch</surname><given-names>T</given-names></name><name><surname>von Messling</surname><given-names>V</given-names></name></person-group>. <article-title>Ferret models of viral pathogenesis</article-title>. <source>Virology.</source> (<year>2015</year>) <volume>479&#x02013;480</volume>:<fpage>259</fpage>&#x02013;<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1016/j.virol.2015.03.017</pub-id><?supplied-pmid 25816764?><pub-id pub-id-type="pmid">25816764</pub-id></mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prussia</surname><given-names>A</given-names></name><name><surname>Thepchatri</surname><given-names>P</given-names></name><name><surname>Snyder</surname><given-names>JP</given-names></name><name><surname>Plemper</surname><given-names>RK</given-names></name></person-group>. <article-title>Systematic approaches towards the development of host-directed antiviral therapeutics</article-title>. <source>Int J Mol Sci.</source> (<year>2011</year>) <volume>12</volume>:<fpage>4027</fpage>&#x02013;<lpage>52</lpage>. <pub-id pub-id-type="doi">10.3390/ijms12064027</pub-id><?supplied-pmid 21747723?><pub-id pub-id-type="pmid">21747723</pub-id></mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perwitasari</surname><given-names>O</given-names></name><name><surname>Bakre</surname><given-names>A</given-names></name><name><surname>Tompkins</surname><given-names>SM</given-names></name><name><surname>Tripp</surname><given-names>RA</given-names></name></person-group>. <article-title>siRNA genome screening approaches to therapeutic drug repositioning</article-title>. <source>Pharmaceuticals.</source> (<year>2013</year>) <volume>6</volume>:<fpage>124</fpage>&#x02013;<lpage>60</lpage>. <pub-id pub-id-type="doi">10.3390/ph6020124</pub-id><?supplied-pmid 24275945?><pub-id pub-id-type="pmid">24275945</pub-id></mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Padhy</surname><given-names>BM</given-names></name><name><surname>Gupta</surname><given-names>YK</given-names></name></person-group>. <article-title>Drug repositioning: re-investigating existing drugs for new therapeutic indications</article-title>. <source>J Postgrad Med.</source> (<year>2011</year>) <volume>57</volume>:<fpage>153</fpage>&#x02013;<lpage>60</lpage>. <pub-id pub-id-type="doi">10.4103/0022-3859.81870</pub-id><?supplied-pmid 21654146?><pub-id pub-id-type="pmid">21654146</pub-id></mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pollastri</surname><given-names>MP</given-names></name><name><surname>Campbell</surname><given-names>RK</given-names></name></person-group>. <article-title>Target repurposing for neglected diseases</article-title>. <source>Future Med Chem.</source> (<year>2011</year>) <volume>3</volume>:<fpage>1307</fpage>&#x02013;<lpage>15</lpage>. <pub-id pub-id-type="doi">10.4155/fmc.11.92</pub-id><?supplied-pmid 21859304?><pub-id pub-id-type="pmid">21859304</pub-id></mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tripp</surname><given-names>RA</given-names></name><name><surname>Mark Tompkins</surname><given-names>S</given-names></name></person-group>. <article-title>Antiviral effects of inhibiting host gene expression</article-title>. <source>Curr Top Microbiol Immunol.</source> (<year>2015</year>) <volume>386</volume>:<fpage>459</fpage>&#x02013;<lpage>77</lpage>. <pub-id pub-id-type="doi">10.1007/82_2014_409</pub-id><?supplied-pmid 25007848?><pub-id pub-id-type="pmid">25007848</pub-id></mixed-citation></ref><ref id="B50"><label>50.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nurmatov</surname><given-names>UB</given-names></name><name><surname>Rhatigan</surname><given-names>E</given-names></name><name><surname>Simons</surname><given-names>FE</given-names></name><name><surname>Sheikh</surname><given-names>A</given-names></name></person-group>. <article-title>H1 -antihistamines for primary mast cell activation syndromes: a systematic review</article-title>. <source>Allergy.</source> (<year>2015</year>) <volume>70</volume>:<fpage>1052</fpage>&#x02013;<lpage>61</lpage>. <pub-id pub-id-type="doi">10.1111/all.12672</pub-id><?supplied-pmid 26095756?><pub-id pub-id-type="pmid">26095756</pub-id></mixed-citation></ref><ref id="B51"><label>51.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chung</surname><given-names>KF</given-names></name></person-group>. <article-title>Currently available cough suppressants for chronic cough</article-title>. <source>Lung.</source> (<year>2008</year>) <volume>186</volume>(<issue>Suppl 1</issue>):<fpage>S82</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1007/s00408-007-9030-1</pub-id><?supplied-pmid 17909897?><pub-id pub-id-type="pmid">17909897</pub-id></mixed-citation></ref><ref id="B52"><label>52.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ryan</surname><given-names>T</given-names></name><name><surname>Brewer</surname><given-names>M</given-names></name><name><surname>Small</surname><given-names>L</given-names></name></person-group>. <article-title>Over-the-counter cough and cold medication use in young children</article-title>. <source>Pediatr Nurs</source>. (<year>2008</year>) <volume>34</volume>:<fpage>174</fpage>&#x02013;<lpage>80</lpage>, 184.<?supplied-pmid 18543844?><pub-id pub-id-type="pmid">18543844</pub-id></mixed-citation></ref><ref id="B53"><label>53.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mori</surname><given-names>T</given-names></name><name><surname>Hayashi</surname><given-names>T</given-names></name><name><surname>Hayashi</surname><given-names>E</given-names></name><name><surname>Su</surname><given-names>TP</given-names></name></person-group>. <article-title>Sigma-1 receptor chaperone at the ER-mitochondrion interface mediates the mitochondrion-ER-nucleus signaling for cellular survival</article-title>. <source>PLoS ONE.</source>
<volume>8</volume>:<fpage>e76941</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0076941</pub-id><?supplied-pmid 24204710?><pub-id pub-id-type="pmid">24204710</pub-id></mixed-citation></ref><ref id="B54"><label>54.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mitsuda</surname><given-names>T</given-names></name><name><surname>Omi</surname><given-names>T</given-names></name><name><surname>Tanimukai</surname><given-names>H</given-names></name><name><surname>Sakagami</surname><given-names>Y</given-names></name><name><surname>Tagami</surname><given-names>S</given-names></name><name><surname>Okochi</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Sigma-1Rs are upregulated via PERK/eIF2&#x003b1;/ATF4 pathway and execute protective function in ER stress</article-title>. <source>Biochem Biophys Res Commun.</source> (<year>2011</year>) <volume>415</volume>:<fpage>519</fpage>&#x02013;<lpage>25</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbrc.2011.10.113</pub-id><?supplied-pmid 22079628?><pub-id pub-id-type="pmid">22079628</pub-id></mixed-citation></ref><ref id="B55"><label>55.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pal</surname><given-names>A</given-names></name><name><surname>Fontanilla</surname><given-names>D</given-names></name><name><surname>Gopalakrishnan</surname><given-names>A</given-names></name><name><surname>Chae</surname><given-names>YK</given-names></name><name><surname>Markley</surname><given-names>JL</given-names></name><name><surname>Ruoho</surname><given-names>AE</given-names></name></person-group>. <article-title>The sigma-1 receptor protects against cellular oxidative stress and activates antioxidant response elements</article-title>. <source>Eur J Pharmacol.</source> (<year>2012</year>) <volume>682</volume>:<fpage>12</fpage>&#x02013;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejphar.2012.01.030</pub-id><?supplied-pmid 22381068?><pub-id pub-id-type="pmid">22381068</pub-id></mixed-citation></ref><ref id="B56"><label>56.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vollrath</surname><given-names>JT</given-names></name><name><surname>Sechi</surname><given-names>A</given-names></name><name><surname>Dreser</surname><given-names>A</given-names></name><name><surname>Katona</surname><given-names>I</given-names></name><name><surname>Wiemuth</surname><given-names>D</given-names></name><name><surname>Vervoorts</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Loss of function of the ALS protein SigR1 leads to ER pathology associated with defective autophagy and lipid raft disturbances</article-title>. <source>Cell Death Dis.</source>
<volume>5</volume>:<fpage>e1290</fpage>. <pub-id pub-id-type="doi">10.1038/cddis.2014.243</pub-id><?supplied-pmid 24922074?><pub-id pub-id-type="pmid">24922074</pub-id></mixed-citation></ref><ref id="B57"><label>57.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayashi</surname><given-names>T</given-names></name><name><surname>Su</surname><given-names>TP</given-names></name></person-group>. <article-title>Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca<sup>(2+)</sup> signaling and cell survival</article-title>. <source>Cell</source>. (<year>2007</year>) <volume>131</volume>:<fpage>596</fpage>&#x02013;<lpage>610</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2007.08.036</pub-id><?supplied-pmid 17981125?><pub-id pub-id-type="pmid">17981125</pub-id></mixed-citation></ref><ref id="B58"><label>58.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ochiai</surname><given-names>H</given-names></name><name><surname>Kurokawa</surname><given-names>M</given-names></name><name><surname>Niwayama</surname><given-names>S</given-names></name></person-group>. <article-title>Influence of trifluoperazine on the late stage of influenza virus infection in MDCK cells</article-title>. <source>Antiviral Res</source>. (<year>1991</year>) <volume>15</volume>:<fpage>149</fpage>&#x02013;<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1016/0166-3542(91)90032-M</pub-id><?supplied-pmid 1859203?><pub-id pub-id-type="pmid">1859203</pub-id></mixed-citation></ref><ref id="B59"><label>59.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fujioka</surname><given-names>Y</given-names></name><name><surname>Tsuda</surname><given-names>M</given-names></name><name><surname>Nanbo</surname><given-names>A</given-names></name><name><surname>Hattori</surname><given-names>T</given-names></name><name><surname>Sasaki</surname><given-names>J</given-names></name><name><surname>Sasaki</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>A Ca<sup>(2+)</sup>-dependent signalling circuit regulates influenza A virus internalization and infection</article-title>. <source>Nat Commun</source>. (<year>2013</year>) <volume>4</volume>:<fpage>2763</fpage>. <pub-id pub-id-type="doi">10.1038/ncomms3763</pub-id><?supplied-pmid 24434940?><pub-id pub-id-type="pmid">24434940</pub-id></mixed-citation></ref><ref id="B60"><label>60.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Belser</surname><given-names>JA</given-names></name><name><surname>Katz</surname><given-names>JM</given-names></name><name><surname>Tumpey</surname><given-names>TM</given-names></name></person-group>. <article-title>The ferret as a model organism to study influenza A virus infection</article-title>. <source>Dis Model Mech.</source> (<year>2011</year>) <volume>4</volume>:<fpage>575</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1242/dmm.007823</pub-id><?supplied-pmid 21810904?><pub-id pub-id-type="pmid">21810904</pub-id></mixed-citation></ref><ref id="B61"><label>61.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watanabe</surname><given-names>T</given-names></name><name><surname>Imai</surname><given-names>M</given-names></name><name><surname>Watanabe</surname><given-names>S</given-names></name><name><surname>Shinya</surname><given-names>K</given-names></name><name><surname>Hatta</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>C</given-names></name></person-group>. <article-title>Characterization <italic>in vitro</italic> and <italic>in vivo</italic> of pandemic (H1N1) 2009 influenza viruses isolated from patients</article-title>. J Virol. (<year>2012</year>) <volume>86</volume>:<fpage>9361</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.01214-12</pub-id><?supplied-pmid 22718834?><pub-id pub-id-type="pmid">22718834</pub-id></mixed-citation></ref></ref-list></back></article>